Difference between revisions of "Octreotide (Sandostatin)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_inj.pdf Octreotide (Sandostatin) package insert]</ref><ref>[ | + | Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_inj.pdf Octreotide (Sandostatin) package insert]</ref><ref>[[Media:octreotide.pdf | Octreotide (Sandostatin) package insert (locally hosted backup)]]</ref><ref>[http://www.sandostatin.com Sandostatin manufacturer's website]</ref> |
<br>Route: SC, IV | <br>Route: SC, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Neuroendocrine tumors]] | ||
| + | *[[Thymoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/Octreotide.aspx Octreotide (Sandostatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Octreotide.aspx Octreotide (Sandostatin) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/octreotide-patient-drug-information Octreotide (Sandostatin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | AO Ning, Longastatina, Octreotide, Octreotide Acetate, Octrestatin, Octride, Okeron, PEI XIN, Proclose, QI WEN, Samilstin, Sandostatin, Sandostatina, Sandostatine, YI PU BI Shang, YI PU Ning. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Somatostatin analogs]] | ||
| + | [[Category:Neuroendocrine tumor medications]] | ||
| + | [[Category:Thymoma medications]] | ||
Revision as of 05:41, 14 May 2013
General information
Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Octreotide (Sandostatin) patient drug information (Chemocare)[4]
- Octreotide (Sandostatin) patient drug information (UpToDate)[5]
Also known as
AO Ning, Longastatina, Octreotide, Octreotide Acetate, Octrestatin, Octride, Okeron, PEI XIN, Proclose, QI WEN, Samilstin, Sandostatin, Sandostatina, Sandostatine, YI PU BI Shang, YI PU Ning.